Ascendis Pharma A/S
ASND
279 hedge funds and large institutions have $12.7B invested in Ascendis Pharma A/S in 2025 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 99 increasing their positions, 92 reducing their positions, and 22 closing their positions.
216% more call options, than puts
Call options by funds: $124M | Put options by funds: $39.3M
155% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 22
17% more capital invested
Capital invested by funds: $10.9B → $12.7B (+$1.83B)
13% more funds holding
Funds holding: 247 → 279 (+32)
6% more funds holding in top 10
Funds holding in top 10: 16 → 17 (+1)
8% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 92
0.65% more ownership
Funds ownership: 102.88% → 103.53% (+0.65%)
Top Buyers
Top Sellers
ASND Hedge Fund Activity: Q3 2025 in Review
279 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2025, worth a combined $12.7B — up 17% from $10.9B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new ASND positions and 22 closed out — a net gain of 34 holders — while 99 added to existing stakes and 92 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $164M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $171M.
- 279 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2025, up from 247 in Q2 2025.
- Funds reported $12.7B of Ascendis Pharma A/S stock for Q3 2025, up 17% quarter-over-quarter.
- 56 funds opened new Ascendis Pharma A/S positions in Q3 2025 and 22 closed out, a net change of +34 holders.
- The largest Ascendis Pharma A/S buyer in Q3 2025 was Wellington Management Group, an estimated $164M added.
- The largest Ascendis Pharma A/S seller in Q3 2025 was T. Rowe Price Investment Management, an estimated $171M sold.
Based on aggregated 13F filings for Q3 2025.